These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 160405)
1. In vitro tests of cellular immunity in man. Herberman RB Invest Cell Pathol; 1978; 1(3):227-48. PubMed ID: 160405 [TBL] [Abstract][Full Text] [Related]
2. Effects on cancer patients of leukapheresis with the continuous-flow blood cell separator. II. Immunologic parameters in vitro. Waldman SR; Roth JA; Kern DH; Pilch YH J Lab Clin Med; 1975 Dec; 86(6):950-61. PubMed ID: 127818 [TBL] [Abstract][Full Text] [Related]
3. Depressed lectin-dependent and enhanced antibody-dependent cell-mediated cytotoxicity in patients with stage I cancer of the larynx. Perl A; Repassy G; Gonzalez-Cabello R; Lang I; Gergely P Nat Immun Cell Growth Regul; 1986; 5(2):100-6. PubMed ID: 3487714 [TBL] [Abstract][Full Text] [Related]
6. [Current tests for the "in vitro" immunologic exploration in man]. Kenzari M Arch Inst Pasteur Tunis; 1979; 56(1-2):39-52. PubMed ID: 121050 [TBL] [Abstract][Full Text] [Related]
7. [Cellular base immunologic recognition. I. Relationship and cooperative interaction between subpopulations of T- and B-lymphocytes during the process of primary immunologic recognition]. Brondz BD Usp Sovrem Biol; 1977; 84(5):219-35. PubMed ID: 27026 [No Abstract] [Full Text] [Related]
9. Assessment of cellular immune response to cancer of the breast. Herberman RB Ann Clin Lab Sci; 1979; 9(6):467-73. PubMed ID: 229763 [TBL] [Abstract][Full Text] [Related]
10. Cell-mediated cytotoxicity in vitro: target-cell recognition and effector-cell requirements. Perlmann P; Holm G; Stejskal V Transplant Proc; 1973 Dec; 5(4):1625-9. PubMed ID: 4272822 [No Abstract] [Full Text] [Related]
11. Cellular (T cell) immunity in the human newborn. Stiehm ER; Winter HS; Bryson YJ Pediatrics; 1979 Nov; 64(5 Pt 2 Suppl):814-21. PubMed ID: 159431 [TBL] [Abstract][Full Text] [Related]
12. Tolerant T cells inhibit natural killer cells function in antigen-presenting cells in an independent fashion. Wang X; Yuan J; Hu J; Wu J; Gan C; He W; Luo G Transplant Proc; 2009 Jun; 41(5):1844-7. PubMed ID: 19545741 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of human antibody-dependent cellular cytotoxicity, cell-mediated cytotoxicity, and natural killing by a xenogeneic antiserum prepared against "activated" alloimmune human lymphocytes. Neville ME; Hiserodt JC J Immunol; 1982 Mar; 128(3):1246-51. PubMed ID: 6976989 [TBL] [Abstract][Full Text] [Related]
15. Assessment of host immune response in breast cancer patients. Akimoto M; Ishii H; Nakajima Y; Iwasaki H; Tan M; Abe R; Kasai M Cancer Detect Prev; 1986; 9(3-4):311-7. PubMed ID: 3488806 [TBL] [Abstract][Full Text] [Related]
16. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. Howell DN; Andreotti PE; Dawson JR; Cresswell P J Immunol; 1985 Feb; 134(2):971-6. PubMed ID: 3871222 [TBL] [Abstract][Full Text] [Related]
17. In vitro correlates of cell-mediated immunity in the human. Bach JF Boll Ist Sieroter Milan; 1974; 53(1):suppl:161-73. PubMed ID: 4277530 [No Abstract] [Full Text] [Related]
18. Leukocyte adherence inhibition to myelin basic protein by cancer patients' T-lymphocytes in association with class II major histocompatibility antigens on monocytes. Thomson DM; Halliday WJ; Phelan K J Natl Cancer Inst; 1985 Dec; 75(6):995-1003. PubMed ID: 2415744 [TBL] [Abstract][Full Text] [Related]
19. Immunologic monitoring of the renal transplant recipient. Suthanthiran M; Garovoy MR Urol Clin North Am; 1983 May; 10(2):315-25. PubMed ID: 6222530 [No Abstract] [Full Text] [Related]
20. Problems in the use of in vitro assays for monitoring cell-mediated immunity in cancer patients. de Vries JE Bull Cancer; 1976; 63(2):279-86. PubMed ID: 791397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]